Patents by Inventor Luc Montagnier

Luc Montagnier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5221610
    Abstract: Polypeptides encoded by the nef gene of Human Immunodeficiency Virus (HIV), which is the major etiological agent of Acquired Immune Deficiency Syndrome (AIDS), are identified. The polypeptides, a diagnostic method for detecting antibodies to HIV in biological fluids, a diagnostic kit for carrying out the method, and pharmaceutical compositions containing the polypeptides are described. The polypeptides are useful in viral vaccines and for the early detection of HIV infection in humans.
    Type: Grant
    Filed: September 4, 1991
    Date of Patent: June 22, 1993
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique
    Inventors: Luc Montagnier, Herve Rochat, El M. Bahraoui, Solange Chamaret, Stephane Ferris, Claude Granier, Jurphaar V. Rietschoten, Jean-Marc Sabatier
  • Patent number: 5217861
    Abstract: Protein compositions containing proteins of the lymphadenopathy virus, which compositions are used for diagnosis of antibodies of such protein in biological fluids, especially blood serum, for the detection or absence of infection. Such compositions contain typically the p18, p13 and/or p25 proteins.
    Type: Grant
    Filed: February 12, 1988
    Date of Patent: June 8, 1993
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Vezinet-Brun, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Theresa Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret
  • Patent number: 5208321
    Abstract: Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.
    Type: Grant
    Filed: May 25, 1989
    Date of Patent: May 4, 1993
    Assignee: Institut Pasteur
    Inventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
  • Patent number: 5173400
    Abstract: Protein compositions containing the p18 and p25 proteins of the lymphadenopathy virus are used for detecting antibodies in blood serum as indicative of infection by such virus. The proteins can be used in various conventional ways to perform immunoassays for the detection of the antibodies.
    Type: Grant
    Filed: October 22, 1991
    Date of Patent: December 22, 1992
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Jean C. Chermann, Francoise Barre-Sinoussi, Francoise Vezinet-Brun, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie Theresa Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret
  • Patent number: 5169763
    Abstract: A viral vector comprising at least a portion of the genome of the HIV virus, a gene coding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression of the glycoprotein in cells, wherein the gp160 is expressed as a non-cleavable protein.
    Type: Grant
    Filed: September 24, 1991
    Date of Patent: December 8, 1992
    Assignee: Transgene S.A., Institut Pasteur
    Inventors: Marie-Paule Kieny, Guy Rautmann, Jean-Pierre Lecocq, Simon W. Hobson, Marc Girard, Luc Montagnier
  • Patent number: 5135864
    Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS. A kit for in vitro assay of LAS or AIDS is provided.
    Type: Grant
    Filed: November 5, 1987
    Date of Patent: August 4, 1992
    Assignees: Institut Pasteur, The United States of America as represented by the Secretary of The Department of Health and Human Services
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
  • Patent number: 5079342
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: February 11, 1987
    Date of Patent: January 7, 1992
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 5066782
    Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399.It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis.It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hydridization probes, derived from the RNA of HIV-2.
    Type: Grant
    Filed: January 10, 1990
    Date of Patent: November 19, 1991
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, Francois Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
  • Patent number: 5055391
    Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency Virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.
    Type: Grant
    Filed: January 3, 1990
    Date of Patent: October 8, 1991
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 5051496
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: January 16, 1987
    Date of Patent: September 24, 1991
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 5034511
    Abstract: A variant of a LAV virus, designated LAV.sub.ELI and capable of causing AIDS. The cDNA and antigens of the LAV.sub.ELI virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Grant
    Filed: April 13, 1987
    Date of Patent: July 23, 1991
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 5030718
    Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.
    Type: Grant
    Filed: January 10, 1990
    Date of Patent: July 9, 1991
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 5030714
    Abstract: A variant of the LAV virus, designated LAV.sub.MAL and capable of causing AIDS. The cDNA and antigens of the LAV.sub.MAL virus can be used for the diagnosis of AIDS and pre-AIDS.
    Type: Grant
    Filed: April 13, 1987
    Date of Patent: July 9, 1991
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Pierre Sonigo, Simon Wain-Hobson, Luc Montagnier
  • Patent number: 4839288
    Abstract: The invention relates to a new variety of retroviruses designated human immunodeficiency virus type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.
    Type: Grant
    Filed: March 3, 1986
    Date of Patent: June 13, 1989
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 4798797
    Abstract: A retrovirus B-LAV associated with lymphadenopathies and with Acquire Immune Deficiency Syndrome, being adapted to B lymphocytes and capable of being continuously produced by continuous cell lines of B lymphoblastoid cells; continuous cell lines of B lymphoblastoid cells which produce the B-LAV retrovirus and a process for producing such cell lines are disclosed.
    Type: Grant
    Filed: October 24, 1986
    Date of Patent: January 17, 1989
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Solange Chamaret, Jacqueline Gruest
  • Patent number: 4759929
    Abstract: A novel method of treating acquired immune deficiency syndromes in warm-blooded animals comprising administering to warm-blooded animals an amount of a non-toxic, pharmaceutically acceptable salt selected from the group consisting of alkali metal, alkaline earth metal and ammonium salts of 9-antimonio-III-21-tungsto-VI-sodate -III-21-tungsto-VI-sodate sufficient to combat acquired immune deficiency syndromes.
    Type: Grant
    Filed: February 5, 1987
    Date of Patent: July 26, 1988
    Assignee: Cabinet Harle & Phelip
    Inventors: Jean-Claude Chermann, Dominique Dormont, Etienne Vilmer, Bruno Spire, Francoise Barre-Sinoussi, Luc Montagnier, Willy Rozenbaum
  • Patent number: 4708818
    Abstract: Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS), including Lymphadenopathy Associated Virus (LAV), are isolated from the sera of patients afflicted with Lymphadenopathy Syndrome (LAS) or AIDS. LAV is a Human Immunodeficiency Virus (HIV). Viral extract, structural proteins and other fractions of the retrovirus immunologically recognize the sera of such patients. Immunological reaction is used to detect antibodies that specifically bind to antigenic sites of the retrovirus in samples of body fluids from patients with AIDS or risk of AIDS. A kit for in vitro assay of LAS or AIDS is provided.
    Type: Grant
    Filed: October 8, 1985
    Date of Patent: November 24, 1987
    Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human Services
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Brun-Vezinet, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Therese Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret, Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
  • Patent number: 4444776
    Abstract: The invention relates to compounds of formula: ##STR1## wherein R'.sub.1 =H, OH or an alkyl group, preferably a lower alkyl group, alkylthio or alkoxy, an halogen or an amino group,R'.sub.2 =H or a lower alkyl group.These compounds have antitumoral and antiviral properties useful for the treatment of cancers in lower animals.
    Type: Grant
    Filed: November 21, 1980
    Date of Patent: April 24, 1984
    Assignee: Agence Nationale de Valorisation de la Recherche (A N V A R)
    Inventors: Emile Bisagni, Claire Ducrocq, Christian Rivalle, Pierre Tambourin, Francoise Wendling, Jean-Claude Chermann, Luc Montagnier
  • Patent number: 4434290
    Abstract: The novel derivatives correspond to the general formula: ##STR1## in which R.sub.1 is a Y--(CH.sub.2).sub.n --NR.sub.4 R.sub.5 group, where Y represents a single bond or the group ##STR2## R.sub.4 and R.sub.5, identical or different, are hydrogen or an alkyl radical, preferably a lower alkyl, or again form together a ring which can include heteroatoms, in particular nitrogen atoms. n is a number ranging from 1 to 10, notably from 2 to 7, R.sub.2 is a hydrogen atom, a lower alkyl group or an aralkyl group in which the alkyl substituent is a lower alkyl group, and R.sub.3 is a hydrogen atom or a CH.sub.3 group useful for the treatment of leukemias.
    Type: Grant
    Filed: May 1, 1981
    Date of Patent: February 28, 1984
    Assignee: Agence Nationale de Valorisation de la Recherche
    Inventors: Emile Bisagni, Claire Ducrocq, Christian Rivalle, Pierre Tambourin, Francoise Wendling, Alain Civier, Luc Montagnier, Jean-Claude Chermann, Jacqueline Gruest, Rosette Lidereau
  • Patent number: 4266060
    Abstract: The invention relates to compounds of formula: ##STR1## wherein R'.sub.1 =H, OH or an alkyl group, preferably a lower alkyl group, alkylthio or alkoxy, an halogen or an amino group,R'.sub.2 =H or a lower alkyl group.These compounds have antitumoral and antiviral properties useful for the treatment of cancers.
    Type: Grant
    Filed: April 13, 1978
    Date of Patent: May 5, 1981
    Assignee: Agence Nationale de Val orisation de la Recherche (ANVAR)
    Inventors: Emile Bisagni, Claire Ducrocq, Christian Rivalle, Pierre Tambourin, Francoise Wendling, Jean-Claude Chermann, Luc Montagnier